Skip to content

H.R. 3162 · 119th Congress (2025–2027)

Affordable and Safe Prescription Drug Importation Act of 2025

This bill expands the categories of prescription drugs that may be imported into the United States and the countries from which such drugs may be imported.

Current law allows the Department of Health and Human Services (HHS) to authorize importation of certain eligible prescription drugs from Canada if HHS certifies that doing so would pose no additional risk to public health and safety, among other requirements. HHS long declined to make the requisite certification, citing safety concerns (e.g., contamination, counterfeiting), but ultimately made the certification in 2020 and has since approved one state plan to import drugs.

The bill removes the certification requirement and requires HHS to issue regulations that permit importation of qualifying prescription drugs from the United Kingdom, Switzerland, and member states of the European Union, in addition to Canada. After one year, if HHS determines that importation of drugs from these countries has been conducted safely, HHS may authorize importation from other countries that meet certain requirements.

The bill also expands the types of prescription drugs eligible for importation to include, for example, biologics such as insulin.

Further, the bill allows individuals to use an eligible licensed foreign pharmacy to fill a U.S.-issued prescription for a qualifying drug for personal use. Currently, an individual seeking to import a prescription drug generally must acquire a waiver from HHS.

Finally, the bill imposes criminal penalties for websites that sell counterfeit drugs or dispense drugs without a required prescription.

Show official title

To amend the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals.

Referred to committee

Latest actionReferred to committee

This bill’s path

This is H.R. 3162’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

Sponsor
Rep. Janice D. Schakowsky (D-IL-9)
Cosponsors
9 cosponsors

5 original · 4 later

9 D

  1. Rep. Steve Cohen (D-TN-9)· Original · May 1, 2025
  2. Rep. Lloyd Doggett (D-TX-37)· Original · May 1, 2025
  3. Rep. Ilhan Omar (D-MN-5)· Original · May 1, 2025
  4. Rep. Chellie Pingree (D-ME-1)· Original · May 1, 2025
  5. Rep. Mark Pocan (D-WI-2)· Original · May 1, 2025
  6. Rep. Yassamin Ansari (D-AZ-3)· Later · Jul 22, 2026
  7. Rep. Greg Casar (D-TX-35)· Later · Aug 3, 2026
  8. Del. Eleanor Holmes Norton (D-DC)· Later · Aug 3, 2026
  9. Rep. Joe Neguse (D-CO-2)· Later · Oct 9, 2026
Policy area
Health

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest

    Referred to committee

    Referred to the House Committee on Energy and Commerce.

    Sources

Committees

  1. HouseEnergy and CommerceReferred May 1, 2025

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (2)
  1. Affordable and Safe Prescription Drug Importation Act of 2025

    Display title, Short title · Introduced in House

  2. To amend the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals.

    Official title · Introduced in House